Terumo's drug-eluting stent, Nobori, nabbed a bit of Abbott Laboratories' Xience glory as it proved in a large study to be just as effective as the top-selling American brand.
Researchers at the U.K.'s University of Cambridge are developing a way to alter DNA in such a way that would allow certain drugs to pass through cell membranes without a hitch.
In a real-life setting, diabetic children fare better with an artificial pancreas than with a sensor-augmented insulin pump when it comes to controlling night-time glucose levels, a new study concludes.
Researchers at the Washington University School of Medicine in St. Louis have taken steps toward the creation of a gel made from bee venom that, when applied vaginally, could help prevent the spread of HIV.
Celgene's $13 million investment in Presage Biosciences' cancer drug delivery platform is a major bet on something groundbreaking. The technology is the first of its kind, with the ability to compare treatments across separate sections of a tumor.
Israeli drug-delivery company PolyPid has partnered with U.S.-based devicemaker MIS Implants Technologies to develop a dual polymer-lipid bone-healing technology specifically for dental use.
Yale researchers have developed a new nanogel delivery platform to treat autoimmune diseases such as lupus, multiple sclerosis and Type 1 diabetes.
Actium BioSystems is testing a novel delivery system for treating cancer that employs both heat and chemotherapy in a selectively targeted attack.
California delivery-device outfit Mercator MedSystems got the OK from European officials to launch two of its micro-infusion catheters, which use tiny needles to deliver drugs directly across artery walls.
Researchers in the U.K. have found that an estrogen patch is an effective way to treat prostate cancer compared with side effects-laden hormone injections and pills.
Swedish researchers have developed trackable nanoparticles that may be a more targeted and effective delivery tool in the fight against cancer.
West Pharmaceutical Services rolled out an adapter for standard needles that enables easier and more consistent delivery into a patient's skin at a very shallow angle.
Researchers at Genzyme have found a way to deliver drugs that shut down the genes associated with the neuromuscular disease myotonic dystrophy type 1, a type of muscular dystrophy.
Ocular Therapeutix is formally seeking premarket approval with the FDA for its hydrogel-based sealant used to protect the eye after cataract surgery.
Researchers at the University of Pennsylvania have found a way to coat small drug-delivery vehicles and other foreign objects with a synthetic "passport" peptide that fools the immune system into allowing the objects to survive longer in the human body.
Drug-delivery devicemaker SHL is expanding its Taiwan venture by $40 million U.S. this year, investing in facilities for its line of auto injectors, pen injectors and inhalers.
Roche's Genentech picked up FDA approval for its late-stage breast cancer therapy Kadcyla, formerly T-DM1, which uses antibodies to deliver cancer drugs directly to the offending cells.
Neuralstem's spinal cord delivery platform will get the academic treatment as the company licensed the stem cell therapy for research at Cedars-Sinai Medical Center in Los Angeles.
In an effort to bring the first-ever sublingual option for the treatment of severe respiratory allergies to the U.S., French company Stallergenes awaits approval from the FDA for its hay fever treatment Oralair.
A federal appeals court decided in favor of Cephalon in a dispute with Actavis ($ACT) over an oral mucosal drug delivery patent.